Comparison of efficacy of GP versus NP as first-line chemotherapy for advanced triple-negative breast cancer
Objective To compare the efficacy of GP(gemcitabine+cisplatin)versus NP(vinorelbine+cisplatin)as first-line chemotherapy for advanced triple-negative breast cancer.Methods 84 patients with advanced triple-negative breast cancer were randomly divided into a control group and an observation group according to the random numerical table,with 42 cases in each group.The clinical efficacy and incidence of toxic side effects after treatment were compared between the two groups.Results After treatment,the total effective rate of the observation group and the control group was both 42.86%,and there was no difference in comparison(P>0.05).After treatment,the incidence of anemia,alopecia,impaired liver function,thrombocytopenia,nausea and vomiting,and leukopenia in the observation group were 30.95%,28.57%,33.33%,33.33%,61.90%,and 66.67%,and those in the control group were 28.57%,30.95%,33.33%,33.33%,59.52%,and 71.43%,and there was no difference in comparison(P>0.05).Conclusion Both GP and NP as first-line chemotherapy for advanced triple-negative breast cancer has better efficacy and treatment safety,and have no significant differences,which can be used as the first choice of treatment for advanced triple-negative breast cancer.These two regimens can be selected clinically according to the actual situation of patients.
Advanced triple-negative breast cancerFirst-line chemotherapyGemcitabineVinorelbineCisplatin
万方数据
维普
